<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011416</article-id><article-id pub-id-type="publisher-id">ACM-38873</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_56321773.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  CD4
  <sup>＋</sup>T淋巴细胞计数在ANCA相关性血管炎患者治疗过程中的变化及其意义
  The Significance of CD4
  <sup>＋</sup>T Lymphocyte Count during the Treatment of Patients with ANCA-Associated Vasculitis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>静月</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>阳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>小凡</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>鹏丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>怿鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>广群</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院心内科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院肾内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2733</fpage><lpage>2737</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨CD4
   <sup>＋</sup>T淋巴细胞计数在ANCA相关性血管炎患者治疗过程中的变化及其意义。方法：选择青岛大学附属医院2019年1月1日~2020年8月1日在肾内科初诊为AAV的患者35例，检测患者活动期和缓解期CD4
   <sup>＋</sup>T淋巴细胞计数、白细胞计数、淋巴细胞计数、中性粒细胞计数、C反应蛋白(CRP)、白蛋白(ALB)、估算的肾小球滤过率(eGFR)、血肌酐(Scr)、BVAS评分及红细胞沉降率(ESR)的变化，并分析BVAS评分与CD4+T淋巴细胞计数之间的关系。结果：缓解期患者BVAS评分、白细胞计数、中性粒细胞计数、ALB、CRP、ESR均显著下降，而CD4
   <sup>＋</sup>T淋巴细胞、ALB治疗后均显著升高，而淋巴细胞计数、Scr、eGFR比较差异均无统计学意义(P &gt; 0.05)。Spearman相关性分析显示，活动期时患者BVAS评分与CD4
   <sup>＋</sup>T淋巴细胞计数呈显著负相关关系(r = −0.398, P &lt; 0.05)。结论：AAV患者治疗不同时期CD4
   <sup>+</sup>T淋巴细胞计数有明显的变化，监测血清中CD4
   <sup>+</sup>T淋巴细胞计数可以指导AAV患者的临床治疗。
    Objective: To investigate the changes and significance of CD4
   <sup>＋</sup>T lymphocyte count during the treatment of patients with ANCA-related vasculitis. Methods: Thirty-five patients who were newly diagnosed with AAV in the Department of Nephrology from Qingdao University Hospital from January 1, 2019 to August 1, 2020 were selected to detect CD4
   <sup>+</sup>T lymphocyte counts, white blood cell counts, lymphocyte counts, medium Changes in neutrophil count, C-reactive protein (CRP), albumin (ALB), estimated glomerular filtration rate (eGFR), blood creatinine (Scr), BVAS score and erythrocyte sedimentation rate (ESR), and analyzed the relationship between BVAS score and CD4
   <sup>+</sup>T lymphocyte count. Results: BVAS score, white blood cell count, neutrophil count, ALB, CRP, and ESR of patients in remission stage decreased significantly, while CD4
   <sup>＋</sup>T lymphocytes and ALB increased significantly after treatment, but there was no difference in lymphocyte count, Scr, eGFR Statistical significance (P &gt; 0.05). Spearman correlation analysis showed that there was a significant negative correlation between the BVAS score and CD4
   <sup>+</sup>T lymphocyte count of patients in the active phase (r = −0.398, P &lt; 0.05). Conclusion: The CD4
   <sup>+</sup>T lymphocyte counts of AAV patients have significant changes in different periods of treatment. Monitoring the serum CD4+T lymphocyte counts can guide the clinical treatment of AAV patients. 
  
 
</p></abstract><kwd-group><kwd>ANCA相关性血管炎，CD4+T淋巴细胞计数，感染, ANCA-Associated Vasculitis</kwd><kwd> CD4+T Lymphocytes</kwd><kwd> Infection</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨CD4<sup>＋</sup>T淋巴细胞计数在ANCA相关性血管炎患者治疗过程中的变化及其意义。方法：选择青岛大学附属医院2019年1月1日~2020年8月1日在肾内科初诊为AAV的患者35例，检测患者活动期和缓解期CD4<sup>＋</sup>T淋巴细胞计数、白细胞计数、淋巴细胞计数、中性粒细胞计数、C反应蛋白(CRP)、白蛋白(ALB)、估算的肾小球滤过率(eGFR)、血肌酐(Scr)、BVAS评分及红细胞沉降率(ESR)的变化，并分析BVAS评分与CD4<sup>+</sup>T淋巴细胞计数之间的关系。结果：缓解期患者BVAS评分、白细胞计数、中性粒细胞计数、ALB、CRP、ESR均显著下降，而CD4<sup>＋</sup>T淋巴细胞、ALB治疗后均显著升高，而淋巴细胞计数、Scr、eGFR比较差异均无统计学意义(P &gt; 0.05)。Spearman相关性分析显示，活动期时患者BVAS评分与CD4<sup>＋</sup>T淋巴细胞计数呈显著负相关关系(r = −0.398, P &lt; 0.05)。结论：AAV患者治疗不同时期CD4<sup>+</sup>T淋巴细胞计数有明显的变化，监测血清中CD4<sup>+</sup>T淋巴细胞计数可以指导AAV患者的临床治疗。</p></sec><sec id="s2"><title>关键词</title><p>ANCA相关性血管炎，CD4<sup>+</sup>T淋巴细胞计数，感染</p></sec><sec id="s3"><title>The Significance of CD4<sup>+</sup>T Lymphocyte Count during the Treatment of Patients with ANCA-Associated Vasculitis<sup> </sup></title><p>Jingyue Zhou<sup>1</sup>, Yang Su<sup>2</sup>, Xiaofan Zhang<sup>1</sup>, Pengli Gao<sup>1</sup>, Yipeng Chen<sup>1</sup>, Guangqun Xing<sup>1*</sup></p><p><sup>1</sup>Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/50-1571681x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 20<sup>th</sup>, 2020; published: Nov. 27<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/50-1571681x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the changes and significance of CD4<sup>＋</sup>T lymphocyte count during the treatment of patients with ANCA-related vasculitis. Methods: Thirty-five patients who were newly diagnosed with AAV in the Department of Nephrology from Qingdao University Hospital from January 1, 2019 to August 1, 2020 were selected to detect CD4<sup>+</sup>T lymphocyte counts, white blood cell counts, lymphocyte counts, medium Changes in neutrophil count, C-reactive protein (CRP), albumin (ALB), estimated glomerular filtration rate (eGFR), blood creatinine (Scr), BVAS score and erythrocyte sedimentation rate (ESR), and analyzed the relationship between BVAS score and CD4<sup>+</sup>T lymphocyte count. Results: BVAS score, white blood cell count, neutrophil count, ALB, CRP, and ESR of patients in remission stage decreased significantly, while CD4<sup>＋</sup>T lymphocytes and ALB increased significantly after treatment, but there was no difference in lymphocyte count, Scr, eGFR Statistical significance (P &gt; 0.05). Spearman correlation analysis showed that there was a significant negative correlation between the BVAS score and CD4<sup>+</sup>T lymphocyte count of patients in the active phase (r = −0.398, P &lt; 0.05). Conclusion: The CD4<sup>+</sup>T lymphocyte counts of AAV patients have significant changes in different periods of treatment. Monitoring the serum CD4<sup>+</sup>T lymphocyte counts can guide the clinical treatment of AAV patients.</p><p>Keywords:ANCA-Associated Vasculitis, CD4<sup>+</sup>T Lymphocytes, Infection</p><disp-formula id="hanspub.38873-formula56"><graphic xlink:href="//html.hanspub.org/file/50-1571681x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1571681x8_hanspub.png" /> <img src="//html.hanspub.org/file/50-1571681x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>抗中性粒细胞胞浆抗体(anti-neutrophil cytoplasmic antibody, ANCA)相关性血管炎(ANCA-associated vasculitis, AAV)是一种可以累及肾脏、肺脏及耳鼻喉等全身多脏器的系统性血管炎。根据2012年Chapel Hill分类，主要分为显微镜下多血管炎(microscopic polyangiitis, MPA)、肉芽肿性多血管炎(granulomatosis with polyangiitis, GPA)和嗜酸性肉芽肿性多血管炎(eosinophilic granulomatosis with polyangiitis, EGPA) [<xref ref-type="bibr" rid="hanspub.38873-ref1">1</xref>]。有研究表明，CD4<sup>＋</sup>T淋巴细胞参与了AAV的病情的进展 [<xref ref-type="bibr" rid="hanspub.38873-ref2">2</xref>]，但是CD4<sup>+</sup>T细胞变化的意义尚未阐明。本文就初诊为AAV患者缓解期和活动期2个时间节点探讨CD4<sup>＋</sup>T淋巴细胞变化在AAV中的临床价值，从而为疾病提供更好的治疗方案。</p></sec><sec id="s6"><title>2. 资料与方法</title><p>回顾性分析我院2018年1月1日~2020年8月1日于我院肾内科初诊为AAV的患者，并于活动期和缓解期均检测过CD4<sup>＋</sup>T淋巴细胞细胞计数的AAV患者共35例，检测患者活动期和缓解期CD4<sup>＋</sup>T淋巴细胞计数、白细胞计数、淋巴细胞计数、中性粒细胞计数、C反应蛋白(CRP)、白蛋白(ALB)、估算的肾小球滤过率(eGFR)、血肌酐(Scr)、伯明翰系统性血管炎活动性评分(BVAS) [<xref ref-type="bibr" rid="hanspub.38873-ref3">3</xref>] 及红细胞沉降率(ESR)的变化，并分析BVAS评分与CD4<sup>+</sup>T淋巴细胞计数之间的关系。患者各时期的BVAS评分通过查看病历和实验室检查计算，eGFR运用CKD-EPI [<xref ref-type="bibr" rid="hanspub.38873-ref4">4</xref>] 公式计算。该研究已经获得相应的伦理许可。</p><p>采用SPSS21.0统计软件进行数据分析整理，计数资料以例数表示，符合正态分布计量资料以 x &#175; &#177; s表示，活动期和缓解期前后比较采用配对样本t检验分析；不符合正态分布计量资料以M(P<sub>25</sub>, P<sub>75</sub>)表示，活动期和缓解期前后比较用Wilcoxon检验分析。CD4<sup>＋</sup>T淋巴细胞计数与BVAS评分之间的关系采用Spearman相关性分析。以P &lt; 0.05为差异有统计学意义。</p></sec><sec id="s7"><title>3. 结果</title><p>35例患者中男19例，女16例，平均年龄63.14 &#177; 11.45岁，最大年龄77岁，最小年龄19岁，平均体重64.20 &#177; 13.80 kg，最大体重100 kg，最小体重35 kg。缓解期患者BVAS评分、白细胞计数、中性粒细胞计数、ALB、CRP、ESR均显著下降，而CD4<sup>＋</sup>T淋巴细胞、ALB治疗后均显著升高，而淋巴细胞计数、Scr、eGFR比较差异均无统计学意义(P &gt; 0.05)。见表1。Spearman相关性分析显示，活动期时患者BVAS评分与CD4<sup>＋</sup>T淋巴细胞计数呈显著负相关关系(r = −0.398, P &lt; 0.05)见图1、图2。ANCA相关性血管炎患者治疗不同时期CD4<sup>+</sup>T淋巴细胞计数有明显的变化，监测血清中CD4<sup>+</sup>T淋巴细胞计数可以指导AAV患者的临床治疗。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of indicators before and after the active phase and remission phase of AAV patients (n = 35</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >活动期检测</th><th align="center" valign="middle" >缓解期检测</th><th align="center" valign="middle" >统计值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >BVAS</td><td align="center" valign="middle" >16.00 (15.00, 18.00)</td><td align="center" valign="middle" >6.00 (5.00, 7.62)</td><td align="center" valign="middle" >Z = −5.168</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >WBC (*10<sup>9</sup>/L)</td><td align="center" valign="middle" >10.51 &#177; 4.61</td><td align="center" valign="middle" >8.43 &#177; 2.80</td><td align="center" valign="middle" >t = 2.435</td><td align="center" valign="middle" >0.020</td></tr><tr><td align="center" valign="middle" >NE (*10<sup>9</sup>/L)</td><td align="center" valign="middle" >8.59 (5.68, 11.42)</td><td align="center" valign="middle" >6.05 (5.22, 7.62)</td><td align="center" valign="middle" >Z = −2.801</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >LY (*10<sup>9</sup>/L)</td><td align="center" valign="middle" >1.05 (0.66, 1.46)</td><td align="center" valign="middle" >1.06 (0.62, 1.61)</td><td align="center" valign="middle" >Z = −0.735</td><td align="center" valign="middle" >0.462</td></tr><tr><td align="center" valign="middle" >CD4<sup>+</sup>T (cell/ml)</td><td align="center" valign="middle" >281.00 (118.00, 412.00)</td><td align="center" valign="middle" >402.00 (238.00, 782.00)</td><td align="center" valign="middle" >Z = −3.784</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >ALB (g/L)</td><td align="center" valign="middle" >30.98 &#177; 6.20</td><td align="center" valign="middle" >32.81 &#177; 5.48</td><td align="center" valign="middle" >t = −2.540</td><td align="center" valign="middle" >0.016</td></tr><tr><td align="center" valign="middle" >Scr (mmol/L)</td><td align="center" valign="middle" >158.30 (86.00, 399.20)</td><td align="center" valign="middle" >134.40 (85.30, 285.90)</td><td align="center" valign="middle" >Z = −0.368</td><td align="center" valign="middle" >0.713</td></tr><tr><td align="center" valign="middle" >CRP (mg/L)</td><td align="center" valign="middle" >31.65 (3.09, 75.51)</td><td align="center" valign="middle" >4.87 (3.10, 8.90)</td><td align="center" valign="middle" >Z = −3.767</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >ESR (mm/h)</td><td align="center" valign="middle" >33.00 (20.00, 53.00)</td><td align="center" valign="middle" >16.00 (11.00, 30.30)</td><td align="center" valign="middle" >Z = −3.407</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >eGFR [ml/(min*1.73m<sup>2</sup>)]</td><td align="center" valign="middle" >30.65 (9.78, 61.38)</td><td align="center" valign="middle" >35.96 (16.12, 71.21)</td><td align="center" valign="middle" >Z = −0.147</td><td align="center" valign="middle" >0.883</td></tr></tbody></table></table-wrap><p>表1. AAV患者活动期和缓解期前后各指标比较(n = 35)</p><p>图1. AAV患者活动期CD4<sup>+</sup>淋巴细胞计数相关性分析</p><p>图2. AAV患者缓解期CD4<sup>+</sup>T淋巴细胞计数相关性分析</p></sec><sec id="s8"><title>4. 讨论</title><p>AAV是一组以小血管壁炎症和纤维素样坏死为特征的系统性自身免疫性疾病，可累积全身多个系统。大剂量的激素和免疫抑制剂的使用极大地提高了AAV患者的长期生存率，同时也是导致AAV患者发生感染的重要危险因素 [<xref ref-type="bibr" rid="hanspub.38873-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38873-ref6">6</xref>]。T细胞介导的免疫反应被认为在AAV的发病机制中起重要作用。CD4<sup>＋</sup>T淋巴细胞亚群的异常可能参与了AAV的发病，可能对疾病的持续状态有着重要作用，而且在AAV患者中发现持续激活的T淋巴细胞，并且与AAV的严重程度呈正相关 [<xref ref-type="bibr" rid="hanspub.38873-ref7">7</xref>]。相关研究表明T淋巴细胞的衰竭在决定自身免疫性疾病的结局中起着核心作用，对这一过程的靶向操作可能会带来新的治疗机会 [<xref ref-type="bibr" rid="hanspub.38873-ref8">8</xref>]。相关研究报道，在GPA患者活动期时CD4<sup>＋</sup>T淋巴细胞水平明显低于缓解期，可能是在抗原的触发下，CD4<sup>＋</sup>T淋巴细胞在活动期选择性的迁移至炎症部位的结果 [<xref ref-type="bibr" rid="hanspub.38873-ref2">2</xref>]。Sakatsume等发现新月体肾炎患者肾组织浸润的T细胞与患者尿T细胞表型均为CD4<sup>＋</sup>T淋巴细胞 [<xref ref-type="bibr" rid="hanspub.38873-ref9">9</xref>]。而且Abdulahad等 [<xref ref-type="bibr" rid="hanspub.38873-ref10">10</xref>] 研究证实尿液中的CD4<sup>＋</sup>T淋巴细胞的出现反映了AAV患者肾损害程度。</p><p>本研究中， AAV患者初诊时CD4<sup>＋</sup>T淋巴细胞数量明显减少，并且与BVAS评分呈负相关。我们推测AAV患者初诊时CD4<sup>＋</sup>T淋巴细胞数量的下降可能与AAV活动时导致CD4<sup>＋</sup>T淋巴细胞发生凋亡，是免疫过度激活从而引起免疫失衡的结果。AAV患者初诊时CD4<sup>＋</sup>T淋巴细胞明显下降是AAV活动的现象，不能因为CD4<sup>＋</sup>T淋巴细胞数量的下降而放弃激素和免疫制剂的使用，此时经过积极治疗，可明显降低感染率的发生。本研究存在一定的局限性，我院诊治的AAV患者虽然较多，但符合该研究的纳入和排除标准的研究人群并不多，且纳入的重症AAV患者较多，这可能对结果有一定的影响，需要后期加大样本量更进一步证实。综上，使用激素及免疫抑制剂治疗后发生感染住院的AAV患者，淋巴细胞和CD4<sup>＋</sup>T淋巴细胞减少与死亡相关，因此，在AAV治疗过程中密切监测患者的淋巴细胞及其亚群计数具有重要意义。</p></sec><sec id="s9"><title>文章引用</title><p>周静月,苏 阳,张小凡,高鹏丽,陈怿鹏,邢广群. CD4<sup>＋</sup>T淋巴细胞计数在ANCA相关性血管炎患者治疗过程中的变化及其意义The Significance of CD4<sup>＋</sup>T Lymphocyte Count during the Treatment of Patients with ANCA-Associated Vasculitis[J]. 临床医学进展, 2020, 10(11): 2733-2737. https://doi.org/10.12677/ACM.2020.1011416</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38873-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jennette, J.C., Falk, R.J., Bacon, P.A., et al. (2013) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis &amp; Rheumatology, 65, 1-11. &lt;br&gt;https://doi.org/10.1002/art.37715</mixed-citation></ref><ref id="hanspub.38873-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Abdulahad, W.H., van der Geld, Y.M., Stegeman, C.A., et al. (2006) Persistent Expansion of CD4+ Effector Memory T Cells in Wegener’s Granulomatosis. Kidney International, 70, 938-947. &lt;br&gt;https://doi.org/10.1038/sj.ki.5001670</mixed-citation></ref><ref id="hanspub.38873-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jennette, J.C., Falk, R.J., Andrassy, K., Bacon, P.A., Churg, J., Gross, W.L., Hagen, E.C., Hoffman, G.S., Hunder, G.G., Kallenberg, C.G., et al. (1994) Nomenclature of Systemic Vasculitides. Proposal of an International Consensus Conference. Arthritis &amp; Rheumatology, 37, 187-192. &lt;br&gt;https://doi.org/10.1002/art.1780370206</mixed-citation></ref><ref id="hanspub.38873-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro 3rd, A.F., Feldman, H.I., Kusek, J.W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A New Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 150, 604-612.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-150-9-200905050-00006</mixed-citation></ref><ref id="hanspub.38873-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Itabashi, M., Takei, T., Yabuki, Y., et al. (2010) Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan. Nephron Clinical Practice, 115, c21-c27. &lt;br&gt;https://doi.org/10.1159/000286346</mixed-citation></ref><ref id="hanspub.38873-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Fauci, A.S., Dale, D.C. and Wolff, S.M. (1974) Cyclophosphamide and Lymphocyte Subpopulations in Wegener’s Granulomatosis. Arthritis &amp; Rheumatology, 17, 355-361. &lt;br&gt;https://doi.org/10.1002/art.1780170404</mixed-citation></ref><ref id="hanspub.38873-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kallenberg, C.G. (2011) Pathogenesis of ANCA-Associated Vasculitis, an Update. Clinical Reviews in Allergy &amp; Immunology, 41, 224-231. &lt;br&gt;https://doi.org/10.1007/s12016-011-8258-y</mixed-citation></ref><ref id="hanspub.38873-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">McKinney, E.F., Lee, J.C., Jayne, D.R., et al. (2015) T-Cell Exhaustion, Co-Stimulation and Clinical Outcome in Autoimmunity and Infection. Nature, 523, 612-616. &lt;br&gt;https://doi.org/10.1038/nature14468</mixed-citation></ref><ref id="hanspub.38873-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sakatsume, M. and Gejyo, F. (2003) Effector T Cells and Macrophages in Urine as a Hallmark of Systemic Vasculitis Accompanied by Crescentic Glomerulonephritis. Nephrology Dialysis Transplantation, 18, 607-609.  
&lt;br&gt;https://doi.org/10.1093/ndt/18.3.607</mixed-citation></ref><ref id="hanspub.38873-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Abdulahad, W.H., Kallenberg, C.G., Limburg, P.C., et al. (2009) Urinary CD4+ Effector Memory T Cells Reflect Renal Disease Activity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis &amp; Rheumatology, 60, 2830-2838. &lt;br&gt;https://doi.org/10.1002/art.24747</mixed-citation></ref></ref-list></back></article>